JP2022535609A5 - - Google Patents
Info
- Publication number
- JP2022535609A5 JP2022535609A5 JP2021573165A JP2021573165A JP2022535609A5 JP 2022535609 A5 JP2022535609 A5 JP 2022535609A5 JP 2021573165 A JP2021573165 A JP 2021573165A JP 2021573165 A JP2021573165 A JP 2021573165A JP 2022535609 A5 JP2022535609 A5 JP 2022535609A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- adc
- alkyl
- treatment
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908233.8A GB201908233D0 (en) | 2019-06-10 | 2019-06-10 | Combination therapy |
| GBGB1908234.6A GB201908234D0 (en) | 2019-06-10 | 2019-06-10 | Combination therapy |
| GB1908233.8 | 2019-06-10 | ||
| GB1908234.6 | 2019-06-10 | ||
| PCT/EP2020/065880 WO2020249528A1 (en) | 2019-06-10 | 2020-06-08 | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535609A JP2022535609A (ja) | 2022-08-09 |
| JP2022535609A5 true JP2022535609A5 (cg-RX-API-DMAC7.html) | 2023-06-13 |
| JP7740994B2 JP7740994B2 (ja) | 2025-09-17 |
Family
ID=71103360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573165A Active JP7740994B2 (ja) | 2019-06-10 | 2020-06-08 | 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220305132A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3980079A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7740994B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220020332A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114302745A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020292965B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142645A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288716B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015403A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202113092WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020249528A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240197783A1 (en) | 2021-04-21 | 2024-06-20 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
| US20260060969A1 (en) * | 2022-08-04 | 2026-03-05 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
| EP4585596A4 (en) * | 2022-09-09 | 2025-12-10 | Shanghai Yingli Pharm Co Ltd | Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof |
| US12706617B2 (en) | 2023-04-27 | 2026-08-11 | Hewlett Packard Enterprise Development Lp | Selective filtering to reduce interferences in Wi-Fi communications |
| US12609718B2 (en) | 2023-06-14 | 2026-04-21 | Hewlett Packard Enterprise Development Lp | WiFi-7 optimized split band architecture and method of operation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| WO2008005268A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| AU2011229862B2 (en) | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| PT2906248T (pt) * | 2012-10-12 | 2019-03-04 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
| BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
| DK2839860T3 (da) * | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| DK2906298T3 (en) * | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) * | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201506399D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201602356D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017160954A1 (en) * | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3612839A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
| KR102442736B1 (ko) * | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| GB201806022D0 (en) * | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA3107085A1 (en) * | 2018-08-31 | 2020-03-05 | Adc Therapeutics Sa | Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax |
| WO2020109251A1 (en) * | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Dosage regime |
| CN111410666B (zh) * | 2019-01-04 | 2021-02-19 | 苏州亚盛药业有限公司 | 一种制备磺胺类化合物的工艺 |
| CA3245067A1 (en) * | 2022-02-28 | 2023-08-31 | Adc Therapeutics Sa | DOSAGE REGIMEN |
-
2020
- 2020-06-08 SG SG11202113092WA patent/SG11202113092WA/en unknown
- 2020-06-08 KR KR1020227000169A patent/KR20220020332A/ko active Pending
- 2020-06-08 WO PCT/EP2020/065880 patent/WO2020249528A1/en not_active Ceased
- 2020-06-08 CN CN202080042853.5A patent/CN114302745A/zh active Pending
- 2020-06-08 JP JP2021573165A patent/JP7740994B2/ja active Active
- 2020-06-08 MX MX2021015403A patent/MX2021015403A/es unknown
- 2020-06-08 AU AU2020292965A patent/AU2020292965B2/en active Active
- 2020-06-08 EP EP20733376.6A patent/EP3980079A1/en active Pending
- 2020-06-08 IL IL288716A patent/IL288716B2/en unknown
- 2020-06-08 US US17/617,875 patent/US20220305132A1/en active Pending
- 2020-06-08 CA CA3142645A patent/CA3142645A1/en active Pending